WO2013120795A2 - Système de curiethérapie & détecteur de dose in vivo pour celui-ci - Google Patents

Système de curiethérapie & détecteur de dose in vivo pour celui-ci Download PDF

Info

Publication number
WO2013120795A2
WO2013120795A2 PCT/EP2013/052652 EP2013052652W WO2013120795A2 WO 2013120795 A2 WO2013120795 A2 WO 2013120795A2 EP 2013052652 W EP2013052652 W EP 2013052652W WO 2013120795 A2 WO2013120795 A2 WO 2013120795A2
Authority
WO
WIPO (PCT)
Prior art keywords
detector
dose
sensors
probe
catheter
Prior art date
Application number
PCT/EP2013/052652
Other languages
English (en)
Other versions
WO2013120795A3 (fr
Inventor
Robert Price
Original Assignee
City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City University filed Critical City University
Priority to GBGB1420171.9A priority Critical patent/GB201420171D0/en
Publication of WO2013120795A2 publication Critical patent/WO2013120795A2/fr
Publication of WO2013120795A3 publication Critical patent/WO2013120795A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1014—Intracavitary radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A61N5/1071—Monitoring, verifying, controlling systems and methods for verifying the dose delivered by the treatment plan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1007—Arrangements or means for the introduction of sources into the body
    • A61N2005/1012—Templates or grids for guiding the introduction of sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1014—Intracavitary radiation therapy
    • A61N2005/1018—Intracavitary radiation therapy with multiple channels for guiding radioactive sources

Definitions

  • This invention relates to brachytherapy treatment systems, particularly but not exclusively to high dose rate brachytherapy treatment systems.
  • Other particularly preferred embodiments of the present invention relate to in vivo dose detectors for such systems.
  • BACKGROUND Brachytherapy is a type of radiation therapy in which radioactive materials (variously referred to hereafter as “seeds” or “sources”) are placed in close proximity to, and often in direct contact with, the (typically malignant) tissue being treated.
  • seeds variously referred to hereafter as “seeds” or “sources”
  • sources radioactive materials
  • LDR low dose rate
  • HDR high dose rate
  • LDR low dose rate
  • HDR high dose rate
  • Brachytherapy treatment is appropriate for a variety of different conditions, including inter alia, prostrate tumours, breast tumours, lung cancer, oesophageal cancer, gynaecologic cancers (such as cervical cancer), anal/rectal tumours, sarcomas and head or neck cancers.
  • HDR brachytherapy is used to treat cancer of the rectum, in some instances before conventional surgical procedures are undertaken, and more recently an alternative to those surgical procedures (each of which has inherent risks associated with them).
  • Recent studies of the use of HDR brachytherapy for the treatment of anal or rectal tumours have shown that the use of HDR brachytherapy can significantly reduce the likelihood of the patient having to be provided with a stoma.
  • HDR brachytherapy In a commonplace HDR brachytherapy treatment (hereafter referred to simply as HDR brachytherapy), a plurality of catheters are inserted into the tissue to be treated, and a machine (known as "an afterloader") is controlled by computer to push a single relatively highly radioactive seed (for example of Iridium 192) into each of the catheters.
  • the computer moves the seeds through the catheters in accordance with a patient treatment plan that has been carefully devised to provide an appropriate irradiation dose distribution for the tissue of the particular patient undergoing treatment.
  • the plan defines (for each radioactive seed) a plurality of longitudinal positions within the catheter to which the seed will be moved (the so-called “dwell positions”), and the time that the seed will remain at each of those locations (the so-called “dwell time”).
  • the computer controls the afterloader to move each of the seeds to a first planned dwell position, to leave the seed at that position for the planned dwell time for that position, and then to move the source to the next planned position. This process is repeated until the dose distribution planned for treatment of the patient's tissue has been achieved.
  • OncoSystemTM sold by Nucletron UK Ltd (a Delft Instruments Company) of Nucletron House, Chowley Oak, Tattenhall, Chester CH3 9EX, United Kingdom.
  • the OncoSystemTM consists of a bundle of Nucletron products for treating body- site specific cancers such as breast, rectal or gynecological cancers, and each bundle consists of OncoSmartTM applicators and disposables, and an OncentraTM treatment control system.
  • the OncoSystemTM provides an accurate method of positioning sources inside the patient.
  • a significant drawback of the system is that measurement of the actual dose (as opposed to the planned dose) delivered to the patient is accomplished externally of the patient, and as such in a number of applications is necessarily somewhat inaccurate, principally because there is often a significant amount of tissue (often with varying radiation absorption properties) between the tumour and the skin.
  • Implantable brachytherapy probes (of different construction) that include radiation detectors for sensing the quantity and location of radiation being delivered to a patient during treatment.
  • a presently preferred embodiment of the present invention provides an in-vivo dose detector for an HDR brachytherapy system, the detector comprising first and second sensors that are operable to detect radiation from a source used to irradiate a tissue to be treated in the course of an HDR brachytherapy treatment, wherein said sensors are arranged in said detector so as to be differently orientated from one another.
  • the detector of this embodiment includes two differently orientated sensors, the detector provides a more isotropic response to incident radiation than previously proposed detectors, an effect that can further be enhanced by summing the outputs of each sensor and computing an average dosage reading.
  • the teachings of the present invention provide that by employing a detector with a number (in this particular example, two) of differently orientated sensors, a more symmetrical response to incident radiation can be provided than has hitherto been possible with previously proposed detectors.
  • an intracavitary probe for an HDR brachytherapy system comprising: a holder having a plurality of smaller bores into each of which a catheter may be inserted and a further larger bore into which a detector array or a detector as described herein may be inserted, the probe being configured to hold said catheters and said detector/array in a predetermined positional relationship to one another.
  • a further embodiment of the invention relates to an HDR brachytherapy system
  • a first catheter insertable into a tissue to be treated, and through which a radioactive source can be moved by an afterloader to irradiate the tissue at one or more dwell positions set out in a treatment plan; an in vivo dose detector as described herein movable to a detection position within said tissue to be treated; and means for measuring radiation detected by the detector when the detector is in said detection position and said source is in said one or more dwell positions.
  • an HDR brachytherapy system comprising: an intracavitary probe as described herein; a catheter inserted into one of said smaller bores, and through which a radioactive source can be moved by an afterloader to irradiate tissue at one or more dwell positions set out in a treatment plan; a detector or a detector array as described herein provided in said larger bore; and means for measuring radiation detected by the detector/array when the source is in said one or more dwell positions.
  • Fig. 1 is a schematic representation of a prior art HDR brachytherapy system
  • Fig. 2 is a schematic representation of an OncosmartTM Intracavitary HDR brachytherapy rectal probe
  • Fig. 3 is a schematic representation of an HDR brachytherapy system according to a preferred embodiment of the present invention.
  • Fig. 4 is a schematic representation of a detector
  • Figs. 5(a) to 5(e) are schematic representations of the various steps in a method for producing a detector of the type shown in Fig. 4;
  • Fig. 6 is a flow diagram illustrating a mode of operation of the system
  • Fig. 7 is a schematic representation of the proximal end (i.e. the collar end) of an intracavitary brachytherapy probe according to an embodiment of the present invention
  • Fig. 8 is a schematic longitudinal cross-section of the probe along the line A— A in Fig. 7;
  • Fig. 9 is a schematic representation of a detector array in use with a probe of the type depicted in Fig. 7;
  • Fig. 10 is a schematic representation, in cross-section, of the proximal region of an intracavitary brachytherapy probe according to another embodiment of the present invention
  • Fig. 1 1 is a schematic representation, again in cross-section, of the proximal region of an intracavitary brachytherapy probe according to yet another embodiment of the present invention.
  • Fig. 12 is a schematic illustration of the probe of Fig. 1 1 configured for use in a particular treatment regimen.
  • a prior art brachytherapy system 1 which comprises a computing resource 3, in this instance a PC, and an afterloader 5 which is operable to drive a set of radioactive sources (not shown) into and out of a bundle of catheters 7 that have been inserted into the region of tissue 9 of the patient that is to be treated.
  • a computing resource 3 in this instance a PC
  • an afterloader 5 which is operable to drive a set of radioactive sources (not shown) into and out of a bundle of catheters 7 that have been inserted into the region of tissue 9 of the patient that is to be treated.
  • the position of the catheters 7 in the tissue is verified by any one of a number of imaging systems, for example by means of an ultrasound or x-ray imaging system.
  • the computing resource 3 controls the afterloader 5 in accordance with a treatment plan that has been devised under the supervision of a physician to deliver an appropriate dose of radiation to the tissue that is to be treated by HDR brachytherapy.
  • the treatment plan consists, for each source that is to be inserted into the patient, a list of dwell positions (longitudinal positions within a given catheter to which the source is to be advanced) and a dwell time (a period of time for which the source is stationary at each dwell position) for each of those dwell positions.
  • the treatment plan is carefully devised to deliver an appropriate dose at each position for the tissue to be treated 9, and the deliverance of this dose is typically verified by means of a detector 1 1 placed outside of the patient.
  • the detector may, as shown, be coupled to a second computing resource 4 configured to monitor and record the dose detected by the detector.
  • a second computing resource 4 configured to monitor and record the dose detected by the detector.
  • Fig. 2 is a schematic representation of an OncosmartTM Intracavitary HDR brachytherapy rectal probe (available from Nucletron UK Ltd).
  • the probe 13 consists of a plurality of catheters 15 (equivalent to the catheter bundle 7 of Fig. 1 ) which have been inserted into a sterile cylinder 21 which (in this instance) is to be inserted into the rectum of a patient.
  • the catheters 15 have been fed through a numbered collar 17 which facilitates discrimination between catheters, and a support block 19 which abuts against the patient in use. In this instance eight catheters have been fitted through the collar and support into the cylinder, but a fewer or greater number of catheters may be employed if desired.
  • the sources which are typically of Iridium 192, are of such a size that they can be advanced by the afterloader through the catheters, and depending on the size and shape of the tissue to be treated only a subset of the aforementioned catheters may have sources moved through them.
  • an in vivo dose detector 41 shown schematically in cross-section in Fig. 4, that fits within a catheter 53 (in this particular instance, part of a 4 French catheter 53) and hence can be moved into and out of the probe and the tissue to be treated.
  • the detector 41 comprises a pair of sensors 55, differently orientated relative to one another, that are coupled to a suitable PCB 57, for example a flexible PCB of Kaplan.
  • each sensor 55 comprises a semiconductor diode configured to operate in a PV (photovoltaic) mode without an applied voltage bias, or with an applied bias.
  • the detectors may comprise MOSFETs that have been specifically constructed to be radiation sensitive, or any other device (the like of which are well known to persons skilled in the art) that is responsive to radiation.
  • the sensors each consist of a semiconductor diode used in photovoltaic mode.
  • the sensors each include a pair of electrical contacts 59 that couple the p- 55(i) and n-type 55(ii) semiconductor regions to a suitable measuring device such as an electrometer 43 (shown schematically in Fig. 3).
  • the electrometer measures charge per unit time and the diodes provide a linear response with respect to the applied dose. If the diodes were to comprise MOSFETs, for example, the electrometer would measure a voltage shift, and the MOSFETs could either be withdrawn and interrogated once treatment has been completed or - in a preferred embodiment - interrogated in real time.
  • the sensors 55 and the PCB 57 each include a plurality of so-called bump pads 61 , typically of silver, and as shown in Fig. 4 adjacent pairs of pads 61 have been joined to one another by a small layer of conducting material 63, such as gold. Spaces 65 between the sensors and the substrate have been backfilled with a relatively high strength epoxy resin, such as a silver epoxy resin, and the sensors and substrate have been encapsulated within the catheter by a black epoxy resin 67 that seals the sensors 55 from ambient light.
  • the catheter 53 may also be provided with one or more locating rings (not shown) of known type, such as of nickel or titanium, so that it can be accurately located in images derived from whatever imaging system is being used to locate the catheter in the tissue to be treated.
  • the detector 41 of this embodiment includes two discrete and differently orientated sensors 55, the detector provides a more isotropic response to incident radiation than previously proposed detectors, an effect that can further be enhanced by summing the outputs of each sensor and computing an average dosage reading.
  • the teachings of the present invention provide that by employing a detector with a number (in this particular example, two) of differently orientated sensors, a more symmetrical response to incident radiation can be provided than has hitherto been possible with previously proposed detectors.
  • this embodiment of the invention contemplates the incorporation of a single detector in a catheter
  • another embodiment of the invention contemplates the incorporation of a detector array in a catheter; each detector of the array being as depicted in Fig. 4.
  • the detectors may be provided adjacent to one another in the catheter, or in another arrangement the sensors may be spaced from one another along the length of the catheter.
  • conventional grown p-n junction semiconductors with a relatively asymmetric response to incident radiation are thinned, for example by means of a conventional etching or dethinning process, to provide p-n junction semiconductors that are approximately 150 microns in height and have a more symmetrical response to incident radiation.
  • Bump pads 61 typically of silver are fixed to the thinned semiconductor diode 55 and to the PCB 57 in a known manner, following which - as shown in Fig. 5(a) - a ball 62 of conducting material, for example gold, is provided on each of the diode bump pads (or alternatively to each of the bump pads 61 on one side of the PCB).
  • a thin interface layer 64 of low strength conducting epoxy for example of silver, is provided between the conducting balls and bump pads, and the diode 55 and PCB 57 are pressed together whilst being heated to approximately 130°C to cure the epoxy and couple the diode to the PCB.
  • the next step, shown in Fig. 5(c) is to back fill the space 65 between the diode 55 and the PCB 57 with a high strength epoxy, and then cure that epoxy at approximately 80°C to enclose the junction between the diode 55 and PCB 57.
  • the resulting assembly is then inverted, as shown in Fig. 5(d), and a second diode 55 with bump pads 61 is procured.
  • the second diode is provided with a ball 62 of conducting material, for example of gold, on each of the diode bump pads (or alternatively to each of the bump pads 61 on one side of the PCB), and a thin interface layer 64 of low strength conducting epoxy, for example of silver, is provided between the conducting balls and bump pads.
  • the second diode and PCB are then pressed together whilst being heated to approximately 130 °C to cure the epoxy layer 64, and as will be appreciated by persons skilled in the art, care must be taken at this stage to ensure that the temperature remains below the point where the epoxy fixing the first diode to the other side of the PCB starts to melt.
  • the space 65 between that diode and the PCB is back-filled with high strength epoxy, and then that epoxy is cured at approximately 80 °C.
  • contact wires 59 are fixed to each of the diodes, and the assembly is then fitted into a catheter and encased within the catheter by means of a light-tight black epoxy to provide a detector of the type depicted in Fig. 4.
  • Fig. 3 is a schematic representation of some of the functional components of a brachytherapy system 31 of a preferred embodiment of the present invention shown assembled for HDR brachytherapy of a tissue 9 to be treated.
  • a dose detector 41 has been inserted into one of the catheters 7, 13 which have been inserted into a tissue 9 to be treated.
  • the detector of this illustrated embodiment comprises semiconductor diodes and is connected to an electrometer 43 that is configured to measure charge per unit time, and in the preferred arrangement the detector 41 remains in one known position within the tissue whilst the sources are moved relative to the detector through the catheters.
  • electrometer 43 that is configured to measure charge per unit time
  • Movement of the sources through the catheters is controlled by a known afterloader (not shown in Fig. 3) controlled by a computing resource (also not shown) in accordance with the treatment plan devised for treatment of the tissue to be treated.
  • the system includes a dose database 35 which interfaces with a treatment planning system 33 to load a treatment plan consisting of dwell positions "r" and dwell times "t" for each source that is to be employed.
  • the dose database 35 is configured to have read-only access to the treatment planning system.
  • the dose database 35 interfaces with a planned dose determinator 37 which calculates for each dwell position the planned dose D(r, t) associated with the source remaining at dwell position r for the associated dwell time t.
  • the determinator 37 is also configured to calculate the integrated patient dose jD(r, t) which corresponds to the total dose applied to the tissue 9 thus far in the course of the HDR treatment.
  • the dose determinator 37 is configured to output a signal representative of the planned dose for each dwell position and a signal representative of the planned integrated patient dose thus far in the HDR treatment.
  • Timing circuitry 39 is coupled to the dose database 35, and is configured to measure periods of time corresponding to the planned dwell times t at each dwell location for which the electrometer 43 measures (in this particular instance) the charge resulting from radiation detected by the detector 41 .
  • the electrometer 43 which may be any of a variety of commonly available known electrometers, outputs a signal representative of the amount of charge Q measured for a given dwell position and dwell time t to a comparator 45 which compares Q(t) to D(r, t) to determine in real time whether the actual dose for a given dwell position corresponds to the planned dose for that position.
  • the comparator may also be configured to compare the total measured dose thus far in the procedure with the planned total dose for that stage of the procedure.
  • the comparator 45 outputs a signal representative of the aforementioned comparisons to a reporting system 49 that is preloaded with a set of patient alert criteria 51 .
  • These criteria define when an emergency condition is determined to have occurred, in response to which the procedure must be terminated and the sources withdrawn from the catheters.
  • the alert criteria may set dose thresholds for each dwell position which cannot be exceeded.
  • the alert criteria may be set such that the system monitors the actual dose as a function of time, and is configured such that the dose must be within a set limit, for example +/-5% Other arrangements will be apparent to persons skilled in the art.
  • the sources are withdrawn and the procedure is terminated. Otherwise the reporting system logs the actual dose (optionally versus the planned dose) for each dwell position to provide the physician with an accurate representation of the dose at the dwell position as well as the total dose administered to the patient in the course of the treatment.
  • Fig. 3 may be configured as stand-alone devices or functional software components. In an alternative arrangement one or more of these components may be integrated together.
  • the timer, electrometer and comparator may be configured as a single application specific integrated circuit (ASIC) 47.
  • ASIC application specific integrated circuit
  • the treatment planning system is implemented by a first computing system
  • the controller for the afterloader is implemented by a second computing system
  • the reporting functionality is implemented by a third computing system
  • the detection functionality is implemented by a fourth computing system (communication between these systems being carefully controlled to ensure that there is no possibility of changes made in the detection or reporting system corrupting or changing data held in the HDR control system or the treatment planning system.
  • the aforementioned ASIC may be integrated into a single computing resource operable to maintain the dose database, implement the dose determinator, and provide the reporting system functionality, and it is even conceivable that this computing resource may be that which is provided for control of the afterloader.
  • the computing system controlling the afterloader is provided with the source start position, and the afterloader is controlled to move the source to the predetermined source start position.
  • the afterloader is configured to move the source relatively quickly to the first dwell position (and between subsequent dwell positions) so that only the tissue to be treated at specified dwell positions is subjected to a significant dose.
  • Irradiation of tissue occurs at all times once the source has been advanced into the patient, but once the source is determined to be in a given dwell position, a timer is started. Radiation emitted by the source is then detected in real time and both the charge for that position and the integrated dose for that stage of the procedure are incremented.
  • the detected dose for that dwell position and, optionally, the integrated dose are compared in real time with the planned dose for that position and the planned integrated dose. If either the detected dose for that position or the integrated dose should exceed the corresponding planned dose or integrated dose (determined in accordance with the alert criteria), the operator is alerted, the source is withdrawn and the procedure is terminated.
  • the timer is determined whether the timer has reached the dwell time for that stage of the procedure. If the timer is less than the planned dwell time, detection of radiation is allowed to continue. If the timer is equal to the planned dwell time, the timer is reset and it is determined whether the treatment plan contains any further dwell positions. If the treatment plan does contain further dwell positions, the next source position is loaded and the procedure repeated. If the final dwell position has been reached, the source is withdrawn and the procedure is terminated.
  • the measured and planned doses are stored in the reporting system, and the output of this system may be formatted for use with other treatment planning and patient management software.
  • FIG. 8 is a longitudinal cross-sectional view of the probe along the line A— A in Fig. 7, and Fig. 7 is a view of the probe from the proximal end thereof (i.e. a view from the end that is not inserted into the patient).
  • the same reference numeral is used hereafter where the features of the probe shown in Figs. 7 and 8 are the same as or similar to features of the probe shown in Fig. 2.
  • the probe 80 of this embodiment comprises a sterile cylinder 21 that is coupled at one end to a collar 17 and is passed through a support block that abuts against the patient when the probe is inserted into the patient's body cavity (for example the rectum).
  • the collar (as before) comprises a plurality (in this instance eight) apertures 82 through one or more of which a catheter (not shown) is inserted in use.
  • the apertures are numbered, as shown, to make it easier for an operator to discriminate between catheters.
  • the apertures 82 are arranged to register with catheter bores 84 formed within the sterile cylinder so that sources and/or detectors may be moved into and out of the probe.
  • the collar of this embodiment further comprises with a larger aperture 86 (in this instance a central aperture) that has a radius which is significantly larger than that of the apertures 82 through which catheters may be inserted.
  • the larger aperture 86 registers with a larger bore 88 formed in the sterile cylinder.
  • the larger aperture and bore 86, 88 are provided to enable the probe to be connected to an insertion aid (such as a relatively rigid applicator) which can be used to insert the probe into the patient's body cavity. Once the probe has been inserted the insertion aid can be removed, and the larger bore 88 can then be used to accommodate a detector array of the aforementioned type (namely a catheter with a plurality of detectors of the type depicted in Fig. 4 housed within it). Whilst skilled persons will appreciate that any number of detectors may be included in the array, in an envisaged arrangement ten detectors are provided.
  • the detector array 90 may additionally be employed to screen a part of the patient that does not need to be irradiated.
  • a particular treatment regimen required a source 92 to be advanced into and drawn out of a catheter located in catheter aperture 7, then it may be advantageous to shield patient tissue diametrically opposite the source 92 (i.e. to the right hand side of the probe as indicated in Fig. 9) from radiation. This could readily be accomplished by coating the periphery of a portion of the detector array 90, for example a portion of the sheath, with an appropriate radiation attenuating material 94.
  • Fig. 10 is a schematic representation, in cross-section, of the proximal region of an intracavitary brachytherapy probe 96 according to another embodiment of the present invention.
  • the probe comprises an additional outer sheath 98 into which the sterile cylinder is inserted.
  • the sheath 98 is selectively expandable, and is shown in Fig. 10 in its expanded state. Expansion of the sleeve may be accomplished by filling it with a fluid (preferably a biocompatible or inert fluid), once the probe is inserted into the patient, so as to introduce a space between the periphery of the probe and patient tissue immediately adjacent thereto.
  • a fluid preferably a biocompatible or inert fluid
  • a space between the probe and the patient, as well as affecting the degree to which the patient is irradiated also provides a gap into which one or more detectors, for example detectors of the type described above in connection with Fig. 5, may be inserted (in the preferred embodiment by passing them through catheters inserted in the gap).
  • one or more detectors for example detectors of the type described above in connection with Fig. 5, may be inserted (in the preferred embodiment by passing them through catheters inserted in the gap).
  • Fig. 1 1 is a schematic representation, again in cross-section, of the proximal region of an intracavitary brachytherapy probe according to yet another embodiment of the present invention.
  • the probe 100 also comprises an expandable outer sheath 102 (which sheath is shown fully expanded in Fig. 1 1 ), but in this instance the sheath is configured to have an outer layer 104 and an inner layer 106 that together define a space which is subdivided into smaller chambers 108 and larger chambers 1 10 by a plurality of baffles 1 12.
  • the smaller chambers 108 are each independently expandable and are each configured to receive a catheter (not shown), into which a detector of the type depicted in Fig. 5 may be advanced.
  • the catheter chambers may be, as shown, generally aligned with the catheter bores in the sterile cylinder 21 , or in an alternative arrangement the catheter chambers may be radially offset from the catheter bores.
  • the larger chambers 1 10 are also independently expandable so that neighbouring chambers can be expanded to differing degrees, thereby differentially varying the distance between the probe and the patient (i.e. so that the space between the probe and jacket is asymmetrical about the periphery of the probe).
  • the larger chambers, and optionally also the smaller chambers are configured to be capable of receiving a radiation attenuating liquid - which liquid may be used to shield a region of the patient from irradiation.
  • Fig. 12 is a schematic illustration of the abovementioned treatment regimen (where a source 92 is advanced into and drawn out of a catheter located in catheter aperture 7), but in this embodiment instead of shielding patient tissue diametrically opposite the source 92 by coating the periphery of a portion of the detector array 90, the expandable chambers (identified with reference numeral 1 14) nearest the tissue to be shielded have been filled with an appropriate radiation attenuating fluid.
  • the probes depicted in Figs. 7 to 13 are eminently suitable for use with the apparatus depicted in Fig 3, for example in accordance with the method depicted in Fig. 6.
  • the teachings provided herein provide a detector that can be read using any conventional electrometer to provide total integrated absorbed dose, and that the system can provide integrated and time-resolved absorbed dose, and a direct measure of the absorbed dose close to the tumour site and hence a report of the difference between planned dose and delivered dose.
  • the detector fits within existing catheters the system can readily and quickly be employed to provide in vivo dosimetry for HDR brachytherapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne un détecteur de dose in vivo (41) pour un système de curiethérapie HDR, le détecteur comprenant des premier et second capteurs (55) qui sont aptes à détecter un rayonnement provenant d'une source utilisée pour irradier un tissu à traiter au cours d'un traitement de curiethérapie HDR, lesdits capteurs (55) étant agencés dans ledit détecteur (41) de façon à être orientés de manière différente l'un par rapport à l'autre.
PCT/EP2013/052652 2012-02-15 2013-02-11 Système de curiethérapie & détecteur de dose in vivo pour celui-ci WO2013120795A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1420171.9A GB201420171D0 (en) 2012-02-15 2013-02-11 Brachytheraphy system & in vivo dose detector therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1202622.5 2012-02-15
GB201202622A GB201202622D0 (en) 2012-02-15 2012-02-15 Brachytherapy system & in vivo dose detector therefor

Publications (2)

Publication Number Publication Date
WO2013120795A2 true WO2013120795A2 (fr) 2013-08-22
WO2013120795A3 WO2013120795A3 (fr) 2013-10-10

Family

ID=45930156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/052652 WO2013120795A2 (fr) 2012-02-15 2013-02-11 Système de curiethérapie & détecteur de dose in vivo pour celui-ci

Country Status (2)

Country Link
GB (2) GB201202622D0 (fr)
WO (1) WO2013120795A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016093942A3 (fr) * 2014-10-09 2016-08-18 Duke University Systèmes et procédés de vérification de pose de source pour des procédures de rayonnement de curiethérapie à l'aide de détecteurs de rayonnement en temps réel
WO2018022990A1 (fr) * 2016-07-29 2018-02-01 The Regents Of The University Of Colorado, A Body Corporate Appareil de placement normalisé pour l'étalonnage de produits radiopharmaceutiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046794A1 (fr) 2003-11-07 2005-05-26 Cytyc Corporation Dispositif implantable de detection de rayonnement de radiotherapie et de curietherapie et procedes correspondants
WO2008009917A2 (fr) 2006-07-17 2008-01-24 City University Système de curiethérapie et détecteur de dose in vivo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9401690A (nl) * 1994-10-13 1996-05-01 Industrial Res Bv In een lichaamsvat implanteerbare stent.
US6402689B1 (en) * 1998-09-30 2002-06-11 Sicel Technologies, Inc. Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
SE0502594L (sv) * 2005-11-28 2007-05-29 Micropos Medical Ab En anordning för att mäta administrerad dos i ett målområde
WO2010080905A2 (fr) * 2009-01-08 2010-07-15 The Board Of Regents Of The University Of Texas System Dosimétrie de rayonnement in vivo en temps réel à l'aide de détecteurs de scintillation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046794A1 (fr) 2003-11-07 2005-05-26 Cytyc Corporation Dispositif implantable de detection de rayonnement de radiotherapie et de curietherapie et procedes correspondants
WO2008009917A2 (fr) 2006-07-17 2008-01-24 City University Système de curiethérapie et détecteur de dose in vivo

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016093942A3 (fr) * 2014-10-09 2016-08-18 Duke University Systèmes et procédés de vérification de pose de source pour des procédures de rayonnement de curiethérapie à l'aide de détecteurs de rayonnement en temps réel
US11000702B2 (en) 2014-10-09 2021-05-11 Duke University Systems and methods for the verification of source placement for brachytherapy radiation procedures using real time radiation detectors
WO2018022990A1 (fr) * 2016-07-29 2018-02-01 The Regents Of The University Of Colorado, A Body Corporate Appareil de placement normalisé pour l'étalonnage de produits radiopharmaceutiques

Also Published As

Publication number Publication date
WO2013120795A3 (fr) 2013-10-10
GB201202622D0 (en) 2012-03-28
GB2515714A (en) 2014-12-31
GB201420171D0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
US8790234B2 (en) Brachytherapy system and in vivo dose detector therefor
US11878186B2 (en) Multi-spectral fluorescence for in-vivo determination of proton energy and range in proton therapy
US7831016B2 (en) Radiation dosimetry apparatus and method, and dosimeter for use therein
US8133167B2 (en) Apparatus and method for radiation distribution mapping
US20070153969A1 (en) Radiotherapeutic device
EP2595535B1 (fr) Appareil et procédé pour la cartographie de distribution de rayonnement de faisceau externe
KR100921342B1 (ko) 방사선량 측정장치
US11850092B2 (en) Dual modality endocavity biopsy imaging system and method
Carrara et al. Semiconductor real-time quality assurance dosimetry in brachytherapy
WO2021116756A1 (fr) Système et procédé de détection de rayonnement
WO2013120795A2 (fr) Système de curiethérapie & détecteur de dose in vivo pour celui-ci
US9555263B2 (en) Apparatus, system and method for supporting a brachytherapy
AU2020256211A1 (en) System and method of using temporal measurements of localized radiation to estimate the magnitude, location, and volume of radioactive material in the body
CN102967872A (zh) 一种集成于短距离放射治疗系统的体腔内剂量探测器
US20140142424A1 (en) Dual modality endocavity biopsy imaging system and method
Buzurovic et al. Commissioning and implementation of an implantable dosimeter for radiation therapy
WO2015107179A1 (fr) Applicateur très peu invasif pour dosimétrie de rayonnement in situ
Moonkum et al. A phamtom study: In vivo rectal dosimetry of high dose rate brachytherapy in cervical cancer
Bollinger et al. Clinical considerations and dosimeters for in vivo dosimetry
Sha et al. Evaluation of rectal dose during high-dose-rate intracavitary brachytherapy for cervical carcinoma
Espinoza The development of a silicon detector quality assurance system for high dose rate brachytherapy
Muenkel et al. Feasibility of improving patient’s safety with in vivo dose tracking in intracavitary and interstitial HDR brachytherapy
McLymore et al. Real-Time In Situ Radiation Detection for Mitigating Injury to the Gastrointestinal Tract
Peters Wireless In-Vivo Dosimetry of High Dose Rate Brachytherapy for Prostate Cancer using MOSkin Detectors
McLymore Real-Time Radiation Detection within the Gastrointestinal Tract

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13708104

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase in:

Ref document number: 1420171

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20130211

122 Ep: pct app. not ent. europ. phase

Ref document number: 13708104

Country of ref document: EP

Kind code of ref document: A2